Last reviewed · How we verify
NCT04619589
Characterization of Dyschromic Hypertrophic Scar
trial in Burn Scar in 50 participants. Completed in 28 June 2023.
28 June 2023
Quick facts
| Lead sponsor | Medstar Health Research Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 21 May 2019 |
| Primary completion | 28 June 2023 |
| Estimated completion | 28 June 2023 |
| Sites | 1 location across United States |
Conditions studied
- Burn Scar — all drugs for Burn Scar →
- Hypertrophic Scar — all drugs for Hypertrophic Scar →
- Hyperpigmentation — all drugs for Hyperpigmentation →
- Hypopigmented Scar — all drugs for Hypopigmented Scar →
Sponsor
Medstar Health Research Institute
Who can join
18 and older, any sex, with Burn Scar or Hypertrophic Scar. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Currently, there are limited prevention or treatments available for dyschromia in burn hypertrophic scars (HTSs). The limited available techniques involve transferring melanocytes from unaffected areas to the scar to adjust pigment. These techniques involve the creation of a donor site and do not utilize the cells that may already be present in scars. This study aims to confirm melanocyte presence in regions of hypo- and hyper- pigmented HTS. If melanocytes can be found in regions of hypopigmentation, these scars may be able to be treated in the future by pigmentation stimulators without the need for surgery. Additionally, if pigmentation specific molecules of interest can be found to be up-regulated in hyperpigmented scar, these may be able to be altered by a pharmacotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04619589
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Burn Scar
Currently open trials in the same condition.
- NCT06807021 — Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients · Phase 2, PHASE3 · recruiting
- NCT07213544 — Remimazolam vs Propofol in Laser Burn Cases · Phase 4 · recruiting
- NCT06801626 — Novel Strategies for Reducing Burn Scar Itch · Phase 3 · recruiting
- NCT06122090 — Treatment of Hypopigmented Scars With Bimatoprost · Phase 2 · recruiting
- NCT05423613 — Microneedling for Burn Hypertrophic Scars · NA · active not recruiting
Other Medstar Health Research Institute trials
Trials by the same sponsor.
- NCT07445932 — Palliative Care Intervention to Improve Health Related Quality of Life for Patients on Long-Term LVAD Support · NA · not yet recruiting
- NCT07318545 — Intervention for Chronic Insufficient Sleep in Young Adult Cancer Patients and Survivors · NA · not yet recruiting
- NCT07337642 — Comparing Collared and Collarless Femoral Stems in Primary Total Hip Arthroplasty · NA · recruiting
- NCT07228377 — Digital Intervention for Symptom Management in Cancer and Opioid Sparing Using Virtual Reality (DISCOVR) Study · NA · recruiting
- NCT07223489 — Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the MedStar · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04619589 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medstar Health Research Institute
- Last refreshed: 3 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04619589.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing